16.78USD+15.56%Mkt Cap: 89.62M USDP/E: —Last update: 2026-06-01
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candida…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap89.62M USD
Enterprise Value30.66M USD
Revenue (TTM)858.00K USD
Gross Profit-17.54M USD
Net Income (TTM)-8.98M USD
Revenue/Share0.1520 USD
Last Price16.78 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.68
PEG—
EV/EBITDA-1.01
EV/Revenue35.73
P/S89.29
P/B1.52
EPS (TTM)-1.36
EPS (Forward)-5.40
52W Range
2.16095% of range17.57
52W High17.57 USD
52W Low2.160 USD
Profitability
Gross Margin0.00%
Oper. Margin-4119.34%
EBITDA Margin0.00%
Profit Margin-1046.39%
ROE-15.49%
ROA-14.42%
Growth
Revenue Growth0.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.81M USD
CapEx (TTM)—
FCF Margin-2004.41%
FCF Yield-19.19%
Net Debt-46.64M USD
Net Debt/EBITDA1.54
Balance Sheet
Debt/Equity0.00
Current Ratio12.92
Quick Ratio11.30
Book Value/Sh9.504 USD
Cash/Share8.832 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.30M
Float3.16M
Insiders4.15%
Institutions96.07%
Short Interest
Short Ratio1.0d
Short % Float13.14%
Short % Out.10.92%
Shares Short578.79K
Short (prev mo.)1.41M
Technical
SMA 5010.69 (+57.0%)
SMA 2006.779 (+147.5%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)450.12K
Avg Vol (10d)49.60K
Technical Indicators
RSI (14)65.2
MACD1.2139
MACD Signal1.3791
MACD Hist.-0.1652
BB Upper16.70 USD
BB Middle14.24 USD
BB Lower11.79 USD
BB Width34.43%
ATR (14)0.7384 USD
Vol Ratio (20d)0.05x